Amphera is pleased to announce that the results of the REACTIVE-2 trial in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) […]
‘s-HERTOGENBOSCH, the Netherlands; September 25, 2024. Amphera B.V., a late-stage biotechnology company developing MesoPher cell therapy to treat cancer, announces
Amphera announces publication of the positive results of the phase II trial in resected pancreatic cancer (REACTIVE) in the Journal
Amphera B.V., a late-stage biotechnology company developing MesoPher cell therapy to treat cancer, today announces publication of the results of
Stichting Support Casper has published an interesting video on the results of the Reactive clinical phase II trial in resected
Amphera B.V., a late-stage biotechnology company developing MesoPher cell therapy to treat cancer, reports publication of the positive results of
S-HERTOGENBOSCH, the Netherlands; June 5, 2023. Amphera B.V., a late-stage biotechnology company developing MesoPher cell therapy to treat cancer, today
Lund, Sweden, and ‘s-Hertogenbosch, the Netherlands, April 26, 2023 – Alligator Bioscience AB (“Alligator”) (Nasdaq Stockholm: ATORX) and Amphera B.V.
In the phase II Reactive trial in patients with resected pancreatic cancer, MesoPher demonstrated a statistically significant 2-year Recurrence Free
Amphera is happy to announce that an article on the Reactive phase II trial in resected pancreatic cancer has been
